Sandbox Turky2: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{| border="5" cellpadding="5" | {| border="5" cellpadding="5" | ||
|+ '''GI infection''' | |+ '''GI infection''' | ||
! Pathogen !! Immunocompetent patients !! Immunocompromised patients | ! Pathogen !! Immunocompetent patients !! Immunocompromised patients | ||
|- align="center" | |||
|'''Shigella species''' || [[TMP-SMZ]], 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or [[fluoroquinoloneb]] (e.g., 300 mg ofloxacin, 400 mg norfloxacin [186], or 500 mg ciprofloxacin b.i.d. 3 3 d); [[nalidixic acid]], 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or [[ceftriaxone]] azithromycin [121] || 3 7–10 d | |||
|- align="center" | |- align="center" | ||
| | |style="background:pink" width="20%" |'''Non-typhi species of Salmonella''' || Not recommended routinely (E-I) [59,60], but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, [[TMP-SMZ]] (if susceptible) or [[fluoroquinolone]] as above, b.i.d. 3 5–7 d; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses || 14 d (or longer if relapsing) | ||
|Non-typhi species of Salmonella || Not recommended routinely (E-I) [59,60], but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, [[TMP-SMZ]] (if susceptible) or [[fluoroquinolone]] as above, b.i.d. 3 5–7 d; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses || 14 d (or longer if relapsing) | |||
|} | |} | ||
Revision as of 17:33, 29 May 2015
| Pathogen | Immunocompetent patients | Immunocompromised patients |
|---|---|---|
| Shigella species | TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or fluoroquinoloneb (e.g., 300 mg ofloxacin, 400 mg norfloxacin [186], or 500 mg ciprofloxacin b.i.d. 3 3 d); nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or ceftriaxone azithromycin [121] | 3 7–10 d |
| Non-typhi species of Salmonella | Not recommended routinely (E-I) [59,60], but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) or fluoroquinolone as above, b.i.d. 3 5–7 d; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses | 14 d (or longer if relapsing) |